Cellectis SA
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell p… Read more
Cellectis SA (CLLS) - Total Assets
Latest total assets as of September 2025: $343.05 Million USD
Based on the latest financial reports, Cellectis SA (CLLS) holds total assets worth $343.05 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Cellectis SA - Total Assets Trend (2007–2024)
This chart illustrates how Cellectis SA’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Cellectis SA - Asset Composition Analysis
Current Asset Composition (December 2024)
Cellectis SA's total assets of $343.05 Million consist of 74.9% current assets and 25.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 37.4% |
| Accounts Receivable | $23.04 Million | 6.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.11 Million | 0.3% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2007–2024)
This chart illustrates how Cellectis SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cellectis SA's current assets represent 74.9% of total assets in 2024, a decrease from 79.3% in 2007.
- Cash Position: Cash and equivalents constituted 37.4% of total assets in 2024, down from 68.2% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 7.0% in 2007.
- Asset Diversification: The largest asset category is accounts receivable at 6.0% of total assets.
Cellectis SA Competitors by Total Assets
Key competitors of Cellectis SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Cellectis SA - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Cellectis SA generates 0.11x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Cellectis SA is currently not profitable relative to its asset base.
Cellectis SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.49 | 1.78 | 6.06 |
| Quick Ratio | 1.49 | 1.75 | 6.03 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $72.62 Million | $ 128.78 Million | $ 263.35 Million |
Cellectis SA - Advanced Valuation Insights
This section examines the relationship between Cellectis SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.56 |
| Latest Market Cap to Assets Ratio | 0.42 |
| Asset Growth Rate (YoY) | 14.7% |
| Total Assets | $383.54 Million |
| Market Capitalization | $160.13 Million USD |
Valuation Analysis
Below Book Valuation: The market values Cellectis SA's assets below their book value (0.42 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Cellectis SA's assets grew by 14.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Cellectis SA (2007–2024)
The table below shows the annual total assets of Cellectis SA from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $383.54 Million | +14.74% |
| 2023-12-31 | $334.27 Million | +27.97% |
| 2022-12-31 | $261.22 Million | -31.63% |
| 2021-12-31 | $382.08 Million | -18.62% |
| 2020-12-31 | $469.47 Million | +0.43% |
| 2019-12-31 | $467.47 Million | -6.66% |
| 2018-12-31 | $500.84 Million | +50.46% |
| 2017-12-31 | $332.88 Million | +0.67% |
| 2016-12-31 | $330.68 Million | -11.32% |
| 2015-12-31 | $372.88 Million | +122.83% |
| 2014-12-31 | $167.34 Million | +279.34% |
| 2013-12-31 | $44.11 Million | -61.68% |
| 2012-12-31 | $115.11 Million | -12.72% |
| 2011-12-31 | $131.89 Million | +90.50% |
| 2010-12-31 | $69.23 Million | -24.20% |
| 2009-12-31 | $91.34 Million | +50.15% |
| 2008-12-31 | $60.83 Million | +12.92% |
| 2007-12-31 | $53.87 Million | -- |